Index

Locators in bold refer to tables; those in italic to figures

5HT gene family; see also serotonin receptor
commercially available tests 168
single-nucleotide polymorphisms 92, 167

ARCH gene 165, 167
abrupt cessation of drugs 172, 174, 184; see also drug discontinuation
absolute risk reduction, epidemiology 156
acamprosate 24, 77, 86, 429, 430-431, 441
acetylcholine reuptake inhibitors (AChRIs), cognitive function 376, 489-490, 492, 499
acne, adverse drug effects 193
active comparators, research studies 66
acute dystonia, adverse drug effects 203
acute stress disorder 452; see also trauma and PTSD
adaptoergens, nutraceuticals 228, 243
addiction 439; see also alcohol abuse/dependence
behavioral 438-439, 446
cannabis 436
case vignettes 438
contingency management 426
drug toxicity screens, false positives 441
measures/assessment 427
methamphetamine use disorder 436
opiates 437, 437, 445
post-acute withdrawal syndrome 437
reward pathway disorders 425-427, 426
stimulant and cocaine addiction 434-438, 443
substances of abuse/detection windows 440
ADHD (attention deficit hyperactivity disorder); see also psychostimulants
children and adolescents 268, 269
cognitive function in adults 493-497
comorbidity 22, 33
diagnostic complexity/symptom overlap 27
effect sizes of differing pharmacotherapies 493
heritability 150
off-label drug uses 13
placebo effects 86, 87
adherence to treatment
long-acting injectable drugs 368
outcome mediators 99-100
polypharmacy 109
racial/ethnic differences 246
sex differences 247
therapeutic drug monitoring 130
adjustment disorders, antidepressants 283
adolescents see children and adolescents
ADRA2A gene 161
adenohypophysis hypofunction 224
adverse drug effects 192-193, 213, 214
acne 193
alopecia 193-194
α-receptor binding affinities in SGAs 196
bleeding 194-205
blood dyscrasias 195, 215
bruxism 195
cardiovascular 195-197
case vignettes 195, 209
cause and effect relationships 192
definitions 198
dementia 198
differentiating from lack of efficacy 504-505
differentiating from natural course of illness 287, 309, 310, 501
discontinuation syndrome 170, 198
dopamine receptor binding affinities in SGAs 204
dry mouth 199
estrousgranal side effects 202-203, 207
FSAs vs. SGAs 357-378
gastrointestinal upset 199
hepatic dysfunction 199-200
histamine receptor-binding affinities 212
histamine receptor binding affinities of SGAs 205
hyperhidrosis 200
hyperparathyroidism 200, 200
hyperpolarization 200-201, 201
kidney damage 197-198
lupus erythematosus 198-199, 199
nephrogenic diabetes insipidus 202
neuroleptic malignant syndrome 202
nosebo effect 192, 193
nutraceuticals 231
polypharmacy 108
polycystic ovary syndrome 196-197, 196, 197
sedation/somnolence 205
suicidal ideation 206-207
serotonin syndrome 205
serotonin receptor binding affinities 212-213
serotonin syndrome 205
sexual dysfunction 206, 216
sialorhea 206
tolerance optimization 219, 220
suicidal ideation 206-207
SIADH 207
tardive dyskinesia 207-209, 208, 208
tics 210
tremor 210
weight gain/obesity 210-213, 213, 217, 218
affect, negative symptoms 389-390
affective disorders see mood disorders
affective instability/lability 308
borderline personality disorder 470-471
differential transdiagnostic treatment 31
diagnostic complexity/symptom overlap 2
outcome modulators 94
aggression, impulsive 336-346, 347; see also anger
anticomulsants 338, 349
antipsychotics 338, 339, 350
beta-blockers 340
interruptive explosive disorder 340-341
lithium 337-338
serotonergic drugs 348
aggressive dosing see high-dosing regimes
agitated depression 301
agitation, anxiety disorders signs/symptoms 401
akathisia 202, 401
alcohol abuse/dependence 426, 427-428
alamine aminotransferase (ALT) biomarker 429, 430-431, 441
adamantines 427
anticomulsants 429-433
antidepressants 433, 442
antipsychotics 434
anxiety disorders 433
baclofen 432
comorbidity 33
definitions and terminology 428
detection windows 440
doxylamine 429, 431
diversity across subpopulations 253
gabapentin 429, 431-432
hallucinogens 434
heritability 150
anticipatory, addiction 426
anticonvulsants; see also specific drugs
adverse drug effects 193–194, 199, 206
alcohol use/dependence 429–433
as antipsychotic adjuncts 371–372
anxiety disorders 402, 411, 420–422
borderline personality disorder 481–482
children and adolescents 267
drug discontinuation 127, 183, 187
hepatically impaired patients 272
impulsive aggression 338
lactation 272
mechanism of action 21
multiple pharmacodynamic effects 125
nomenclature/classification 23
nonsuicidal self-injury 352
pharmacokinetic drug interactions 121
pregnancy 271
psychotropic profiles 330
reproductive psychopharmacology 441
suicidal ideation 206
trauma/PTSD 458, 463
antidepressants; see also MAOIs, SNRIs, SSRIIs, tricyclic antidepressants
abrupt cessation issues 172–184
ADHD 496
adjustment disorders 283
adverse drug effects 193–194, 194–205, 206, 207
alcohol abuse 433, 442
antidepressant discontinuation syndromes 172–173
as antipsychotic adjuncts 372
anxiety disorders 302, 402, 410, 416, 417, 418
augmentation vs. switching strategies 288–289
augmentation strategies 289–291, 291–293, 325
bipolar disorder 309, 327
borderline personality disorder 472, 473–474, 480
bupropion 286, 324
children and adolescents 266
choice of 286–288
cocaine addiction 444
cognitive function 489
dosage conversions 176–177, 184
dosing recommendations 319, 320, 321, 322, 323, 324
drug discontinuation 183
efficacy 284
efficacy pharmacogenetics 155
geriatric psychopharmacology 248–249, 250–252, 270
hepatically impaired patients 273
lactation 272
multiple pharmacodynamic effects 126
negative symptoms 392, 399
nomenclature/classification 23
outcome moderators 93
pharmacokinetic drug interactions 120, 121
psychotic depression 300
renat patients 276
sex differences 247
strategies to optimize tolerance 220
suicidal ideation 206
supratherapeutic dosing 286–288, 324
switching vs. augmentation strategies 288–289
therapeutic drug monitoring 135, 142
toleration 283
use of SGAs as augmentation strategy 289–291, 325
anticholinergics; see also specific drugs
adverse drug effects 198, 199
adverse drug effects 200
anxiety disorders 402, 412
antidepressants; see also specific drugs
as antipsychotic adjuncts 372
bipolar disorder 309, 327
borderline personality disorder 472, 473–474, 480
children and adolescents 266
choice of 286–288
cocaine addiction 444
cognitive function 489
dosage conversions 176–177, 184
dosing recommendations 319, 320, 321, 322, 323, 324
drug discontinuation 183
efficacy 284
efficacy pharmacogenetics 155
geriatric psychopharmacology 248–249, 250–252, 270
hepatically impaired patients 273
lactation 272
multiple pharmacodynamic effects 126
negative symptoms 392, 399
nomenclature/classification 23
outcome moderators 93
pharmacokinetic drug interactions 120, 121
psychotic depression 300
renat patients 276
sex differences 247
strategies to optimize tolerance 220
suicidal ideation 206
supratherapeutic dosing 286–288, 324
switching vs. augmentation strategies 288–289
therapeutic drug monitoring 135, 142
toleration 283
use of SGAs as augmentation strategy 289–291, 325
INDEX

inflammatory biomarkers, outcome moderators 98
inflammatory-state
depression 303
psychosis 372–373, 381
individuality, response to medication 7–8; see also precision medicine
inferential statistics, research studies 61

hyperarousal see arousal states
hyperhidrosis, adverse drug effects 200
Hyposperm peroxidum (St. John’s wort) 231, 240
hyperparathyroidism, adverse drug effects 200, 200
hyperprolactinemia, adverse drug effects 200–201, 207, 247, 357–378
hypersalivation, adverse drug effects 296
hypersensitivity reactions, discontinuation of drugs 170
hypertension, abrupt drug cessation 172
hypotension, orthostatic 195–196
hypothalamus, impulsivity/compulsivity 334
hypotheses, research studies 49, 91, 103

influenza pharmacology 118–119, 506; see also high-dosing regimes
illness course see course of illness
illness severity see baseline severity
illness subtype outcome moderators/mediators 98–99, 103

impairment
alcohol use dependence 442
anxiety disorders 417
dosage conversions 185
dosing recommendations 364–383
hepatically impaired patients 274
high-dosing regimes 381
histamine receptor binding affinities 205, 212
impulsive aggression 356
negative symptoms 298–299
protein binding 262
renal patients 277
serotonin receptor binding affinities 290, 408
therapeutic drug monitoring 136, 143, 148

imipramine
alcohol use dependence 442
anxiety disorders 417
dosage conversions 184
dosing recommendations 322
genetic psychopharmacology 270
outcome moderators 96
protein binding 262
serotonin receptor binding affinities 409
therapeutic drug monitoring 141, 143

Impact of Events Scale (IES): 451

impulsivity/compulsivity 333–334, 336–346, 347; see also aggression (impulsive)

OCD
in affective and psychotic disorders 336
brain regions/networks 334–335
case vignettes 340
corticolimbic loop 334
cortico-striatal-thalamo-cortical dysfunction 342
definitions and terminology 333, 335
manic state 345, 352
obsessive-compulsive phenomena 341–344, 351
other disorders of 345–346
salience network 335
serotonergic drugs 337, 342–344, 348
skin excoriation 344–345, 351
somatic marker hypothesis 335
top-down/bottom-up cognition 334
transdiagnostic treatment 37, 41
trichotillomania 345
working memory 335
independent variables, research studies 55
indication bias, adverse drug effects 198
indications for pharmacotherapy 6
individuality, response to medication 7–8; see also precision medicine
inferential statistics, research studies 61

inflammatory biomarkers, outcome moderators 98
inflammatory-state
depression 303
psychosis 372–373, 381
insomnia see sleep aids
insula (anterior insular cortex) 335, 426
insomnia

irritability
irritable bowel syndrome 261
iron supplements 236
irritability 41, 336; see also impulsivity/compulsivity
irritable bowel syndrome 261
isoniazid 165, 199, 234

Jadad Scale, research studies 53

Kava kava (Piper methysticum) 231, 240
ketamine
detection windows 440
mechanism of action 11, 21
NMDA receptors 360
randomized controlled trials 326
treatment-resistant depression 296–300, 299, 326
Ketter’s hypothesis 312
kidney damage 197–198; see also renal patients
kindling paradigm 95
kleptomania 346
Knuskel-Weilis test, research studies 61–62

L-methionine 237
L-carnosine 492
L-methadole 228
L-theanine 237, 396
laboratory drug monitoring see therapeutic drug monitoring
lactation 255, 272; see also reproductive psychopharmacology
LAs see long-acting injectable antipsychotics
Laing, R. D. 389
lamotrigine
abrupt cessation issues 172–184
antidepressant augmentation/adjuncts 292
as antipsychotic adjunct 371
anxiety disorders 420
bipolar depression 312–314, 313, 314, 328
bipolar disorder 307, 312–314, 314
borderline personality disorder 481–482
children and adolescents 267
cognitive function 490
drug interactions 121
hepatically impaired patients 272
impulsive aggression 349

OCD 344
off-label uses 13
placebo effects 81, 81
pregnancy 271
psychotropic profiles 330
renal patients 275
skin excoriation 351
strategies to optimize tolerance 215
therapeutic drug monitoring 134–135, 139

www.cambridge.org
INDEX

measurement-based care (MBC) (cont.)
expermental measures 137-138
objective measures of symptom severity 500-501
secondary outcomes 137, 144

drug monitoring see therapeutic drug monitoring

measurement instruments
 addiction 427
anxiety disorders 415

cognitive function 486-487
negative symptoms in schizophrenia 390
PTSD 450-451

mechanism of drug action 11-12, 21, see also neurotransmitter systems
Medawar, Peter 73

mediators of treatment outcomes see outcome moderators/mediators
medically unexplained physical symptoms (MUPS) 258
metabolism
neurotransmitter systems 20
psychotropic relevance of supplements 238

memantine
alcohol use/dependence 434

borderline personality disorder 476
cognitive function 492, 494, 499

OCD 344

schizophrenia 376

memory 485, 487, see also working memory

messenger circuitry see limbic system

meta-analyses 63-64

funnel plots 64

network 63-64

pitfalls 71

metabolic dysregulation, drug effects 210-213, 213

metabolite glutamate receptors

meta-analyses 297, 360, 361, 362

methadone

drug effects 196
detection windows 440
drug toxicology screens, false positives 441

opioid addiction 437, 445

therapeutic drug monitoring 143

methamphetamine use disorder 436

methyleneoxymethamphetamine see MDMA

methylphenidate

borderline personality disorder 477
children and adolescents 269

cognitive function 493-494
dosage conversions 189

drug interactions 111

genetic psychopharmacology 251-252

half-life of drugs 178

hepatically impaired patients 275

long-acting formulations 494

protein binding 262

renal patients 278

methyldopa

microbiome, brain-gut interactions 229, 243

mineral deficiencies 225, 236, see also nutraceuticals

Mini-Mental Status Exam (MMSE) 456

minocycline 199, 383, 396

mirtazapine

adverse drug effects 216
alcohol use/dependence 442

antidepressant adjuncts 292

anxiety disorders 302, 419

smokers 252

cognitive function 488
dosage conversions 184
dosing recommendations 323

drug interactions 111, 123

genetic psychopharmacology 270

hepatically impaired patients 273

hormone receptor binding affinities 212

impulsive aggression 348

multiple pharmacodynamic effects 126

OCD 344

protein binding 262

renal patients 276

serotonin receptor binding affinities 212-213, 408, 490

sex differences 247

supratherapeutic dosing 324

therapeutic drug monitoring 142, 143

missing at random (MAR) research studies 60

mixed effect models, meta-analyses 63

mixed models for repeated measures (MMRM) 60, 61

MMSE (Mini-Mental Status Exam) 486

modafinil

avoiding polypharmacy 128

children and adolescents 269

cognitive function 492, 494-495
to counter sedation 205

drug interactions 111, 124

hepatically impaired patients 275

off-label uses 13

protein binding 262

renal patients 278

schizophrenia 376

moderation management, controlled drinking 428

moderator analyses, research studies 62-63

moderators of treatment outcomes see outcome moderators/mediators

monoamine oxidase inhibitors see MAOIs

Montreal Cognitive Assessment (MoCA) 486

mood disorders 281-283, 318;
mood stabilizers 292, 303, 396

modulation management, controlled drinking 428

multiple imputation methods, research studies 60

multivariate analyses, research studies 60

multiple diagnoses, cause-and-effect relationships 5

multiple imputation methods, research studies 60

multiple regression models 62

multivariate analyses, research studies 61

muscarinic phospholipases 293

myocardial infarction, and depression 258

myocarditis, adverse drug effects 195

naltrexone 436

N-acetyl-cysteine (NAC) addiction 436

behavioral addictions 446

cognitive function 492

nutraceuticals 241-242

skin excoriation 351

trauma/PTSD 459

nabulol 340

naltrexone 431, 446

naltrexone addiction 426

© in this web service Cambridge University Press
www.cambridge.org
INDEX

observed effects, cause and effect relationships 4-5
observer effect 75
obesities, see also impulsivity/compulsivity, OCD
anxiety disorders signs/symptoms 401
definitions 333
vs. psychosis 38
Obsessive-Compulsive Drinking Scale 427
obsessive-compulsive personality disorder (cluster C) 478
OCD/obsessive-compulsive disorder 341-344, see also impulsivity/compulsivity
with bipolar disorder 317
placebo effects 87
prediction/risk factors for postpartum depression 254
skin exsorption 344-345, 351
odds ratios (ORs), research studies 51
olanzapine
  α receptor binding affinities 196
  antidepressant augmentation/adjuncts 325
anxiety disorders 423-424
behavioral addictions 446
bipolar disorder 332
borderline personality disorder 483-484
cigarette smokers 252
dopamine receptor binding affinities 204
dosage conversions 185
dosing recommendations 384
hepatically impaired patients 274
high-dosing regimes 381
histamine receptor binding affinities 205, 212
impulsive aggression 350
long-acting injectable (LA) 386-387
negative symptoms 398-399
protein binding 262
renal patients 277
serotonin receptor binding affinities 212-213, 290, 408, 490
sex differences 247
short-acting intramuscular injection 367-368
therapeutic drug monitoring 143, 148
trauma/PSTD 464
olanzapine/fluphenazine combination (OFC) 295
old age/older adults see geriatric psychopharmacology
omega-3 fatty acids 241-242, 476
omnibus test, research studies 51
"on-label/off-label" drug treatments 12-13
ondaneston 397, 426, 432
one in ten rule, regression models 62
one-size-fits-all approach, efficacy vs. effectiveness 89
one-carbon donor molecules 227-228
one-tailed tests, research studies 55-56
open-label placebo 82
opiates
  addiction 427, 445
  drug toxicology screens, false positives 441
  metabolism 437
opioid antagonists
  nonsuicidal self-injury/self-injurious behavior 352
  skin exsorption 351
optimism, dispositional 77
oral loading strategies, therapeutic drug monitoring 133-134
orbitofrontal cortex (OFC) 335
orexin neurotransmitter system 20
orthostatic hypotension, adverse drug effects 195-196
Osler, Sir William 89
osmotic release oral delivery system (OROS) formulation, methylphenidate 494
outcome measures see measurement instruments
outcome moderators/mediators 89, 99, 104
adherence to treatment 99-100
age factors/age at onset 94
baseline anxiety disorders 97
bespoke treatment 90, 93
biomarkers as moderators 90-91, 105-106
case vignettes 99
changing one variable at a time 500
childhood trauma 97
chronicity 94-95
cognitive function/emotional processing 101
congfounding factors 92
definitions 90
diffusion tensor imaging 91
drug interactions 99-100
duration of untreated illness 95-96
early and enduring response to treatment 101-102
efficacy vs. effectiveness 89
expressed emotion 101
factors 98
hedonic capacity 101
illness severity 93-94
illness subtype 98-99
inflammatory biomarkers 98
number of episodes 97-98
patient preferences 98
post hoc analyses 103
psychopathology 97
psychosocial factors 98
racial/ethnic differences 96
resilience 97
sex differences 96
for specific conditions 106
suicidal ideation 96
substance misuse 101
switching drug regimens 102-103
Wilder's law 93
alcohol use/dependence 429
anxiety disorders signs/symptoms 401
antidepressant augmentation/adjuncts 325
antidepressant augmentation/adjuncts 325
bipolar disorder 332
borderline personality disorder 483-484
conversion to long-acting injectable 186
dosage conversions 185
dosing recommendations 384
hepatically impaired patients 274
impulsive aggression 350
long-acting injectable (LA) 386-387
negative symptoms 398-399
protein binding 262
renal patients 277
serotonin receptor binding affinities 212-213, 290, 408, 490
sex differences 247
short-acting intramuscular injection 367-368
therapeutic drug monitoring 143, 148
trauma/PSTD 464
sedative hypnotics 20
serotonin neurotransmitter system 20
obsessive-compulsive personality disorder 477
obsessive-compulsive personality disorder 477
negative symptoms 396
schizophrenia 376
trauma/PSTD 458
paliperidone
  α receptor binding affinities 196
  antidepressant augmentation/adjuncts 325
  bipolar disorder 332
  borderline personality disorder 483-484
  conversion to long-acting injectable 186
  dosage conversions 185
  dosing recommendations 384
  hepatically impaired patients 274
  histamine receptor binding affinities 205, 212
  impulsive aggression 350
  long-acting injectable 386-387
  negative symptoms 398-399
  protein binding 262
  renal patients 264, 277
  serotonin receptor binding affinities 212-213, 290, 408, 490
  panic attacks 412
  panic disorder, see also anxiety/GAD
  anxiety disorders signs/symptoms 401
  bupropione 408
  burnout 150

© in this web service Cambridge University Press

www.cambridge.org
INDEX

research studies and statistical analysis (cont.) study group/study population 48, 49 time until event analyses 65 type I error/false positives 54 type II error/false negatives 54 univariate/multivariate analyses 61 resilience borderline personality disorder 476 gyroscope analogy 10 outcome moderators 97 transdiagnostic treatment 38-39 trauma/PSTD 447, 452 retrospective research designs 50 reverse causality 198 reward pathway disorders 335, 425-427 reward-seeking 425, see also addiction risk-benefit analysis, aggressive pharmacology 506-507 risky behaviors, transdiagnostic treatment 41 risperidone adverse drug effects 201 antidepressant augmentation/adjuncts 325 anxiety disorders 423-424 bipolar disorder 332, 333 conversion to long-acting injectable 186 dopamine receptor binding affinities 204 dosage conversions 185 dosing recommendations 385 drug interactions 111 hepatically impaired patients 274 histamine receptor binding affinities 205, 212 impulsive aggression 350 long-acting injectable 386-387 multiple pharmacodynamic effects 127 negative symptoms 398-399 renal patients 277 schizotypal personality disorder 469 serotonin receptor binding affinities 212-213, 290, 490 therapeutic drug monitoring 143, 148 trauma/PSTD 464 ROC curve receiver operating characteristic curves rumination 333, 401 SAD (seasonal affective disorder), placebo effects 87 s-adenosylmethionine (SAMe) 96, 227-228 safety concerns, nutraceuticals 222-223, 231 safety pharmacogenetics 153, 164 cytochrome P450 metabolism 154, 155 enzymes in phase I/phase II hepatic metabolism 164 St. John’s wort, herbal treatments 231, 240 salience network, impulsivity/compulsivity 335 saturation kinetics 131-132 Sayers, Dorothy L. 25 Schedule for the Assessment of Negative Symptoms (SANS) 390 schizoid personality disorder 468-470 schizophrenia, see also negative symptoms adrenochrome hypothesis 224 augmentation strategies 372, 372-373, 375 benzodiazepines 375 cannabidiol 375 case vignettes 175-176 cognition as primary target 375-376 cognitive function 491-493, 499 D-vitamin deficiency 223 diagnostic complexity/symptom overlap 27 drug discontinuation 175-176 drug interactions 111 efficacy of different drugs 365-366 electroconvulsive therapy 375 heritability 150 maintenance vs. discontinuation of therapy 191, 376, 388 outcome moderators 106 pharmacogenetics 158 placebo effects 86, 87 probiotics 243 schizotypal personality disorder 468-470, 491 scopolamine, antidepressant augmentation 293 Screen for Cognitive Impairment for Psychiatry (SCIP) 486 secondary outcomes, research studies 64-65 sedation, adverse drug effects 205 sedatives, see also benzodiazepines; Z-drugs hepatically impaired patients 274 pregnancy 271 renal patients 278 seizes abrupt cessation of drugs 172 adverse drug effects 205 selective serotonin reuptake inhibitors see SSRIts serotonin supplements 226 serotonin receptor adverse drug effects 212-213 antipsychotic adjuncts 372 anxiety disorders 407-410, 408 cognitive function 489-490 depression 291 and dopaminergic system 356-357, 391 negative symptoms 397 OCD 344 polypharmacy 173, 113 psychotropic relevance of supplements 237 SSRIts 290 serotonin syndrome 111-112, 205 serotonin adverse drug effects 195 alcohol use/dependence 442 anxiety disorders 302, 416, 419 behavioral addictions 446 cocaine addiction 444 cognitive function 488-489 dosage conversions 184 dosing recommendations 319 drug interactions 121 efficacy pharmacogenetics 156 geriatric psychopharmacology 250, 270 histamine receptor binding affinities 212 impulsive aggression 348 lactation 255 multiple pharmacodynamic effects 126 outcome moderators 96, 99 postpartum depression 253 protein binding 262 renal patients 276 serotonin receptor binding affinities 212-213, 408 skin excoriation 351 supraphagic dosing 324 therapeutic drug monitoring 140 trauma/PSTD 452-453 serum drug level monitoring, definition 130-131; see also therapeutic drug monitoring
INDEX

trauma/PTSD 463

toxicity states 130, 170

TPH1 gene 78, 167

TPH2 gene, commercially available tests 330

renal patients 264, 275

skin excoriation 351

stimulant use disorder 435

strategies to optimize tolerance 219

588
INDEX

zinc supplements 236
ziprasidone 196
α receptor binding affinities 325
anxiety disorders 423-424
bipolar disorder 332
borderline personality disorder 483-484
dopamine receptor binding affinities 204
dosage conversions 185
dosing recommendations 385
hepatically impaired patients 274
high-dosing regimes 381
histamine receptor binding affinities 205, 212
negative symptoms 398-399
renal patients 277
serotonin receptor binding affinities 212-213, 290, 408, 490
short-acting intramuscular injection 367-368
therapeutic drug monitoring 143, 148
trauma/PTSD 464
zolpidem 274
hepatically impaired patients 274
protein binding 262
sex differences 247
therapeutic drug monitoring 143